- Home
- CYN vs RLYB Comparison
CYN vs RLYB Comparison
Compare CYN & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYN | RLYB |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 24.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYN | RLYB |
|---|---|---|
| Price | $3.92 | $0.80 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 225.1K | 179.7K |
| Earning Date | 11-18-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $457,227.00 | ★ $674,000.00 |
| Revenue This Year | $31.96 | $17.61 |
| Revenue Next Year | $1,459.25 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 347.74 | 12.71 |
| 52 Week Low | $2.62 | $0.22 |
| 52 Week High | $701.25 | $1.24 |
Technical Indicators
Market Signals| Indicator | CYN | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 51.23 | 75.06 |
| Support Level | $3.52 | $0.63 |
| Resistance Level | $3.96 | $0.68 |
| Average True Range (ATR) | 0.31 | 0.04 |
| MACD | 0.12 | 0.01 |
| Stochastic Oscillator | 86.36 | 99.95 |
Price Performance
Historical ComparisonAbout CYN Cyngn Inc.
Cyngn Inc is an industrial autonomous vehicle technology company. Its flagship innovation is DriveMod, an autonomous driving solution that can be flexibly deployed on multiple vehicle types manufactured by Original Equipment Manufacturers in various environments.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.